For research use only. Not for therapeutic Use.
Pagoclone (CAT: M110788), also known by its alternate names CI-1043, IP-456, and RP-62955, emerges as a GABA receptor agonist with potential applications in treating stuttering, panic disorder, and generalized anxiety. This compound’s mechanism of action involves binding to the benzodiazepine binding site on human GABAA receptors, specifically those containing α1, α2, α3, or α5 subunits.
| Catalog Number | M110788 |
| CAS Number | 133737-32-3 |
| Molecular Formula | C23H22ClN3O2 |
| Purity | ≥95% |
| Target | GABA receptor agonist |
| Storage | -20°C |
| Reference | </br>1:Comments on article by Maguire et al: pagoclone trial: questionable findings for stuttering treatment. Ingham RJ.J Clin Psychopharmacol. 2010 Oct;30(5):649-50; author reply 650-1. doi: 10.1097/JCP.0b013e3181f1f130. No abstract available. PMID: 20841975 </br>2:Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study. Maguire G, Franklin D, Vatakis NG, Morgenshtern E, Denko T, Yaruss JS, Spotts C, Davis L, Davis A, Fox P, Soni P, Blomgren M, Silverman A, Riley G.J Clin Psychopharmacol. 2010 Feb;30(1):48-56. doi: 10.1097/JCP.0b013e3181caebbe. PMID: 20075648 </br>3:Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance. Caveney AF, Giordani B, Haig GM.Neuropsychiatr Dis Treat. 2008 Feb;4(1):277-82. PMID: 18728798 Free PMC Article</br>4:Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. de Wit H, Vicini L, Haig GM, Hunt T, Feltner D.J Clin Psychopharmacol. 2006 Jun;26(3):268-73. PMID: 16702891 </br>5:The in vivo properties of pagoclone in rat are most likely mediated by 5/’-hydroxy pagoclone. Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS.Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20. PMID: 16430927 </br>6:A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Lingford-Hughes A, Wilson SJ, Feeney A, Grasby PG, Nutt DJ.Psychopharmacology (Berl). 2005 Aug;180(4):789-91. Epub 2005 Sep 14. No abstract available. PMID: 15986186 </br>7:Pagoclone Indevus. Bateson A.Curr Opin Investig Drugs. 2003 Jan;4(1):91-5. Review. PMID: 12625036 </br>8:Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D/’Orlando KJ, Gammans RE, Nutt DJ.J Psychopharmacol. 2001 Sep;15(3):205-8. PMID: 11565630 |
